



BSW Formulary Updates and Recent Decisions – January 2024

New additions to BSWformulary and Change in Traffic Light Status

- [FreeStyle Libre 3®](#) – The new FreeStyle Libre 3 Sensors (FSL3) recently launched by Abbott have been added to the Drug Tariff. FSL3 sensors are NOT interchangeable with FSL2 Sensors. While we evaluate the provision of these sensors and criteria for use, they have been added with **RED** TL and should not be prescribed in primary care.
- [Riluzole 50mg orodispersible films](#) – Additional formulation added for patients with swallowing difficulties. Added with **AMBER** TL.
- [Lidocaine 4% cream \(LMX4\)](#) – added as an alternative, cost-effective topical anaesthetic for use before venous cannulation or venepuncture with **GREEN** TL.

New and Updated Shared Care Agreements and Prescribing Guidance

- **NEW** – [Daridorexant for long-term insomnia](#) Daridorexant has been added to BSW formulary with. This guidance aims to assist prescribing in primary care.
- **NEW** – [Rimegepant for treating acute migraine](#) Rimegepant has recently been added to BSW formulary with a mixed TLS depending on indication. This guidance aims to assist prescribing Rimegepant for acute treatment in primary care (**GREEN** TL). Use of rimegepant for prevention of migraine has a **RED** TL currently.
- **Updated** – [Management of infection guidance in primary care](#) – Information from recent [MHRA DSU](#) added to support safer prescribing of fluoroquinolones. Giardia treatment options revised; tinidazole has been discontinued and BNF recommended metronidazole.

Minor amendments to Netformulary

External website links added to relevant entries:

- [NHSE Commissioning recommendations for national procurement for DOACs](#)
- [DHSC: Influenza season 2023/24: Use of antiviral medicines](#)
- [SPS: Managing interactions with methotrexate](#)
- [SPS: Use of nefopam for chronic pain](#)
- [NatPSA: Potential for inappropriate dosing of insulin when switching insulin degludec \(Tresiba®\) products](#)
- [PrescQIPP: Right to choose](#)

Minor amendments to information on formulations in [oral glucose](#), [isosorbide mononitrate](#) and [oral liothyronine](#) entries.

What the BSW CCG formulary team are currently working on

- A primary care pathway for treatment and prevention of migraine
- An application to consider the use of cytisine for smoking cessation
- A SCA for valproate in women of childbearing potential, to support ongoing valproate safety work
- Updating local guidance on the use of DOACs in VTE



Bath and North East Somerset,
Swindon and Wiltshire Together

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net